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Abstract
Aims/hypothesis While genome-wide association studies
(GWASs) have been successful in identifying novel variants
associated with various diseases, it has been much more
difficult to determine the biological mechanisms underlying
these associations. Expression quantitative trait loci (eQTL)
provide another dimension to these data by associating
single nucleotide polymorphisms (SNPs) with gene expres-
sion. We hypothesised that integrating SNPs known to be
associated with type 2 diabetes with eQTLs and coexpres-
sion networks would enable the discovery of novel candi-
date genes for type 2 diabetes.
Methods We selected 32 SNPs associated with type 2 dia-
betes in two or more independent GWASs. We used previ-
ously described eQTLs mapped from genotype and gene
expression data collected from 1,008 morbidly obese
patients to find genes with expression associated with these
SNPs. We linked these genes to coexpression modules, and
ranked the other genes in these modules using an inverse
sum score.
Results We found 62 genes with expression associated with
type 2 diabetes SNPs. We validated our method by linking
highly ranked genes in the coexpression modules back to
SNPs through a combined eQTL dataset. We showed that
the eQTLs highlighted by this method are significantly
enriched for association with type 2 diabetes in data from
the Wellcome Trust Case Control Consortium (WTCCC,
p00.026) and the Gene Environment Association Studies
(GENEVA, p00.042), validating our approach. Many of the
highly ranked genes are also involved in the regulation or
metabolism of insulin, glucose or lipids.
Conclusions/interpretation We have devised a novel method,
involving the integration of datasets of different modalities, to
discover novel candidate genes for type 2 diabetes.
Keywords Genetics of type 2 diabetes .
Genomics/proteomics . Mathematical modelling
and simulation
Abbreviations
eQTL Expression quantitative trait locus
eSNP Expression single nucleotide polymorphism
GENEVA Gene-Environment Association Studies
GWAS Genome-wide association study
LD Linkage disequilibrium
SNP Single nucleotide polymorphism
WTCCC Wellcome Trust Case Control Consortium
Introduction
Genome-wide association studies (GWASs) of common com-
plex or multifactorial diseases have proliferated enormously
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over the last few years. They have also been successful in
identifying a large number of loci at extraordinary levels of
significance, given the large cohort sizes. However, this suc-
cess has presented a new challenge: translating these findings
into a full understanding of how the loci affect complex
disease traits. Most of the reported variants do not affect
protein function in an obvious manner and indeed a large
number lie in introns or intergenic regions [1], indicating that
they may function through other regulatory mechanisms such
as control of gene expression or alternative splicing. Even the
gene or genes implicated in a given disease with respect to a
given genetic locus in such cases is not entirely clear, given
that variation near one gene may affect regulation of another
neighbouring gene, or variation in the intron of a protein-
coding gene may affect the regulation of an embedded non-
coding RNA. Variations in DNA affecting the expression of a
gene begs the question of whether such genetic variants, com-
monly known as expression quantitative trait loci (eQTLs), are
an important factor in disease susceptibility [2].
The genes regulated by eQTLs are commonly referred to
as expression traits. The relationship between eQTL geno-
types and expression traits are mapped by performing
GWASs for the expression of all genes in the organism of
interest [3]. This requires simultaneous measurement of
genetic variation (single nucleotide polymorphisms [SNPs])
and gene expression in the same individuals. Multiple hy-
pothesis correction, either through applying a Bonferroni-
adjusted cut-off or more sophisticated methods such as
permutation-based analysis to empirically estimate the null
distribution and control the false discovery rate (FDR), is
then used to filter the association results. The SNPs that tag
eQTLs are commonly referred to as expression SNPs
(eSNPs). However, eQTL-expression trait relationships are
not just statistical associations. Nicolae et al demonstrated
that trait-associated SNPs in general are enriched for eQTLs
[4]. In addition, studies have shown that eQTLs mapped in a
disease-relevant tissue of interest are enriched for disease-
associated SNPs [5, 6]. These insights have been applied to
leverage eQTLs in providing a more relevant context within
which to interpret SNP associations to disease and to priori-
tise GWAS results [6–8]. Other investigators have taken
advantage of the link between genetic variation and gene
expression by integrating eQTLs with coexpression
networks and showing that this is a powerful model for
discovering novel genes and gene networks relevant to
disease [9, 10].
In this study, we demonstrate a novel approach integrat-
ing eQTLs and mouse tissue-specific coexpression networks
with knowledge of genetic variants reproducibly associated
with type 2 diabetes. Our hypothesis was that if the genes
coexpressed with expression traits linked to the well-known
type 2 diabetes SNPs have any explanatory power or bio-
logical relevance for type 2 diabetes, then eSNPs linked
with expression traits for these coexpressed genes should
already have been associated with type 2 diabetes in previ-
ously run case–control GWASs, albeit at a much lower,
indirect level of significance. Showing weaker but consis-
tent levels of significance in case–control studies for these
other eSNPs would potentially serve as a valuable method
for explaining some of the ‘missing heritability’ in the
genetic architecture of complex disease, while at the same
time serving as a method to explain those variants already
discovered in GWASs.
Methods
The overall experimental design is shown in Fig. 1. We first
constructed a comprehensive dataset of eQTLs discovered
in metabolically significant tissues by collecting all SNP–gene
expression relationships with genome-wide significance
reported in liver and subcutaneous and omental adipose tissue
[10, 11].
To identify a starting set of genes associated with type 2
diabetes, we first selected SNPs that had been reproducibly
associated with type 2 diabetes in two or more independent
GWASs. To map these type-2-diabetes-associated SNPs to
candidate causal genes, we used cis SNP-gene associations
(gene to SNP distance within 1 Mb) identified with the
Kruskal–Wallis test at an uncorrected p value cut-off of
0.05 in liver and subcutaneous and omental adipose tissue
of 1,008 morbidly obese patients [10]. In total, there were
508 genes within 1 Mb of these SNPs. We decided that the
higher false-positive rate resulting from this relaxed cut-off
could be tolerated because we planned to use additional
filters to genetically validate any novel associations. We
refer to these type 2 diabetes candidate genes mapped via
eQTLs as type 2 diabetes expression traits.
We obtained previously described tissue-specific coex-
pression subnetworks constructed from gene expression
studies in human tissues [10, 12, 13] and various mouse
crosses, including C57BL6/J×C3H/HeJ on both wild type
[11] and Apoe−/− backgrounds [9, 14], C57BL6/J×A/J [15]
and C57BL6/J×Castaneus [11]. The weighted coexpression
subnetworks were constructed with previously described
methods using the most highly connected nodes from
each tissue [16]. Briefly, the networks are based only on
calculated gene–gene pairwise correlations, with the
modules in these networks identified based on topological
properties in an approach that avoids hard thresholding on
the correlations. The weighted network analysis begins with
a matrix of the Pearson correlations between all gene pairs
and then converts the correlation matrix into an adjacency
matrix using a power function f(x)0xb. The variable b of the
power function is determined in such a way that the result-
ing adjacency matrix, namely the weighted coexpression
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network, is approximately scale-free. By not including
literature, canonical pathways and other such relationships
among genes, the coexpression networks represent a more
unbiased view of the biological processes (reflected in the
modules) at play.
Subnetworks that contained at least one type 2 diabetes
expression trait were selected; these will be referred to as
type 2 diabetes coexpression networks. Genes that appeared
in more of these modules could be considered more likely to
be associated with type 2 diabetes. We therefore scored
genes for type 2 diabetes coexpression by counting the
number of modules they appeared in. Because a gene would
be more likely to be present in a larger module simply by
chance, we weighted the score by taking the inverse of the
network size. Therefore, the type 2 diabetes coexpression
score for each gene was calculated by summing the inverse
of the number of genes in each type 2 diabetes coexpression
network containing that gene, or
Pn
i 1=Si , where n is the
number of networks in which the gene co-occurs with an
expression trait and Si is the number of genes in network i.
The background score was calculated by repeating this
analysis for the genes in all coexpression networks.
Genes were mapped back to eSNPs using the previously
mentioned eQTL dataset containing SNP–RNA relation-
ships of genome-wide significance. To test whether the
eSNPs of genes above a certain score cut-off were enriched
for association to type 2 diabetes, we used SNP summary
statistics provided by the Wellcome Trust Case Control
Consortium (WTCCC). Because the eQTL mapping studies
and the WTCCC assayed SNPs on different platforms with
incomplete overlap, the eSNPs were expanded to include
those in strong linkage disequilibrium (LD; R2>0.8). The
Fig. 1 Integrating replicated disease SNPs with differentially
expressed genes through an eQTL dataset. (a) We mapped 33 SNPs
replicated in more than one GWAS for type 2 diabetes to 62 expression
traits in liver and omental and subcutaneous adipose tissue taken from
morbidly obese individuals. (b) There were 526 coexpression networks
that contained at least one of these expression traits. (c) The score for
each gene in the coexpression networks was calculated by taking the
sum of the inverse of the network sizes in which it appeared. A
background score was also calculated for all coexpression networks,
then the two sets of genes were ranked by score and the Δrank was
recorded. (d) Highly ranked genes with largeΔrank were mapped back
to eSNPs, and we evaluated the distribution of p values of these eSNPs
in data from the WTCCC. The two different models for the permuta-
tions are also shown. Subc, subcutaneous; T2D, type 2 diabetes
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percentage with p<0.05 for type 2 diabetes (pT2D<0.05)
was recorded. Because we would expect type 2 diabetes
expression traits and genes containing type 2 diabetes SNPs
to score highly using our filters, we removed these from the
novel candidate gene lists before performing this evaluation.
We empirically estimated the null distribution of eSNPs
using two different models. For the first model, we randomly
selected half of the genes above a certain score cut-off,
mapped these to eSNPs, expanded into strong LD, and
recorded pT2D<0.05 as above. This was repeated 10,000 times
for each cut-off. For the second model, we randomly selected
33 genes as the initial expression traits used to determine the
subnetworks and repeated the entire analysis. This process
was repeated 1,000 times.
We also used an independent GWAS dataset from the
Gene-Environment Association Studies (GENEVA) Diabe-
tes Study (release Version 2) to validate our findings. This is
a GWAS performed on a total of 3,000 cases and 3,000
controls from two well-characterised cohorts: the Nurses’
Health Study (www.channing.harvard.edu/nhs) and the
Health Professionals Follow-up Study (www.hsph.harvard.
edu/hpfs). We obtained SNP summary statistics through the
Database of Genotypes and Phenotypes (dbGaP; dbGaP
Study Accession: phs000091.v2.p1) and performed the
same permutation analysis by randomly selecting 33 genes
as the initial expression traits.
Results
Type 2 diabetes expression traits We started with 32 SNPs
that have been associated with type 2 diabetes in multiple
studies (Table 1) [17–22]. Using genotype data of 1,008
patients and gene expression profiles of three tissues (omental
adipose, subcutaneous adipose and liver) collected at the time
of gastric bypass surgery [10], we identified genes within
1 Mb of each type 2 diabetes SNP with expression correlated
with the genotype at that locus. In total, only 21 of these 32
type 2 diabetes SNPs were associated with 62 different
expression traits at the uncorrected threshold of p00.05.
Scoring genes using mouse coexpression networks In order
to study these 62 expression traits associated with 21 well-
known type 2 diabetes SNPs, we screened through 2,326
tissue-specific coexpression modules derived from coex-
pression networks constructed as previously described
[9–16]. Out of the 62 type 2 diabetes expression traits, 33
were present in one or more coexpression network modules,
resulting in the implication of 526 type 2 diabetes coexpres-
sion network modules.
Each of the 13,961 genes that were present in any of
these 526 networks could contribute additional explanatory
power as to how those original 21 type 2 diabetes SNPs lead
to diabetes. To study each of these 13,961 genes, we calcu-
lated the type 2 diabetes coexpression score as
Pn
i 1=Si ,
where n is the number of networks in which the gene is
coexpressed with one of the 33 expression traits and Si is the
total number of genes in network i. In order to determine a
baseline or background score, we treated the entire set of
2,326 coexpression modules as describing all human disease
(disease coexpression networks) and calculated the score for
all 13,987 genes that appeared in any of these 2,326 coex-
pression modules. This was done to control for genes pres-
ent in a high percentage of all networks, for example. We
then ranked genes in the type 2 diabetes and background
coexpression score lists from highest to lowest scores and
Table 1 Thirty-two SNPs reproducibly associated with type 2 diabetes
in multiple studies
SNP Chromosome Functional type Adjacent gene
rs7578597a 2 Missense THADA
rs4402960a 3 Intron IGF2BP2
rs1470579a 3 Intron IGF2BP2
rs4607103a 3 Intergenic
rs10010131a 4 Intron WFS1
rs7754840 6 Intron CDKAL1
rs7756992 6 Intron CDKAL1
rs10946398 6 Intron CDKAL1
rs4712523 6 Intron CDKAL1
rs864745a 7 Intron JAZF1
rs13266634a 8 Missense SLC30A8
rs10811661 9 Intergenic
rs564398a 9 Intergenic
rs7903146a 10 Intron TCF7L2
rs12255372a 10 Intron TCF7L2
rs7901695a 10 Intron TCF7L2
rs11196205a 10 Intron TCF7L2
rs7895340a 10 Intron TCF7L2
rs4506565a 10 Intron TCF7L2
rs1111875a 10 Intergenic HHEX
rs5015480a 10 Intergenic HHEX
rs12779790a 10 Intergenic
rs5219 11 Missense KCNJ11
rs2237892a 11 Intron KCNQ1
rs2237895 11 Intron KCNQ1
rs2237897a 11 Intron KCNQ1
rs10830963 11 Intron MTNR1B
rs7961581a 12 Intergenic
rs8050136 16 Intron FTO
rs9939609 16 Intron FTO
rs4430796 17 Intron HNF1B
rs1884613 20 Intergenic
a Serves as an eSNP in liver and adipose tissue
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recorded the Δrank ([Background coexpression rank]−[Type
2 diabetes coexpression rank]) for each gene, resulting in a
type 2 diabetes coexpression rank and Δrank for each gene.
The rank and Δrank for the type 2 diabetes expression traits
are listed in Table 2.
eSNPs of highly ranked genes are enriched for association
with type 2 diabetes As stated above, our hypothesis was
that if the genes coexpressed with expression traits linked to
the well-known type 2 diabetes SNPs have any explanatory
power or biological relevance for type 2 diabetes, then variants
in these genes might have already been associated with type 2
diabetes in case–control studies, albeit at a much lower, indi-
rect, level of significance. We thus evaluated the performance
of the type 2 diabetes coexpression score and rank change for
selecting genes relevant to the pathogenesis of type 2 diabetes.
Of the 13,961 genes coexpressed with the expression traits of
type 2 diabetes SNPs, 6,030 (6,005 excluding type 2 diabetes
expression traits) could be mapped back through eQTLs to
20,480 SNPs that had been tested in the well-known GWAS
on type 2 diabetes, run by the WTCCC.
We selected sets of these 6,005 genes at six type 2
diabetes coexpression rank quantile cut-offs (0, 75, 90, 95,
97.5, 99). Although there was a trend for increasing enrich-
ment of WTCCC pT2D<0.05 in the higher quantiles, it was
not significant. Because we expected genes relevant to type
2 diabetes to have a highΔrank compared with background,
we ordered each quantile by Δrank, then split each set into
those above and below the median Δrank for that quantile.
We compared the WTCCC pT2D<0.05 of the subsets of
genes above and below the median Δrank (Fig. 2a), reveal-
ing the genes with high Δrank in each set to be increasingly
enriched for WTCCC pT2D<0.05 at higher cut-offs and thus
confirming our original hypothesis.
The null distributions for the halves of each quantile were
estimated by randomly selecting half of the genes in each set
and recording the pT2D<0.05. This was repeated 10,000
times. This analysis revealed that the enrichment trend ob-
served in Fig. 2a reached significance at the 99th percentile
cut-off (18.7%, p00.007). We also performed a more strin-
gent estimation of the null distribution by randomly select-
ing 33 genes as the initial expression traits and replicating
the analysis 1,000 times. The result of permutation using
this model was consistent with the first one, with a p value
of 0.026 at the 99th percentile cut-off (Fig. 2b). In order to
validate these findings, we repeated the analysis using SNP
data from the GENEVA diabetes study. A total of 7,047
genes (7,037 excluding type 2 diabetes expression traits)
could be mapped back through eQTLs to 31,011 SNPs
tested in this study. Similar to what we had seen with
WTCCC, we observed significant enrichment (19.5% in
the 99.75th percentile, p00.042) for GENEVA pT2D<0.05
at higher cut-offs.
Table 2 Thirty-three expression traits regulated by type 2 diabetes
SNPs
SNP Adjacent
gene
Expression
trait
T2D
coexpression
rank
ΔRank
rs2237892 KCNQ1 KCNQ1 1 654
rs2237897
rs2237892 KCNQ1 TNNT3 3 1,265
rs1111875 IDE 23 2,508
rs5015480
rs1111875 CYP26A1 27 2,674
rs5015480
rs4607103 ADAMTS9 34 2,840
rs12255372 TCF7L2 VTI1A 35 2,843
rs4506565 TCF7L2 CASP7 42 3,302
rs7895340
rs11196205
rs7901695
rs12255372 TCF7L2 GPAM 43 3,428
rs5015480 PDLIM1 48 3,603
rs1111875
rs2237897 KCNQ1 TH 49 3,610
rs7961581 TSPAN8 51 3,635
rs864745 JAZF1 TAX1BP1 101 5,108
rs10010131 WFS1 MRFAP1 138 5,504
rs564398 CDKN2A 145 5,565
rs10010131 WFS1 CPZ 286 6,449
rs1111875 TMEM20 347 6,701
rs5015480
rs12779790 DHTKD1 471 7,012
rs2237897 KCNQ1 SLC22A18 488 7,047
rs4506565 TCF7L2 DCLRE1A 748 7,483
rs7903146
rs7901695
rs10010131 WFS1 JAKMIP1 1,288 7,748
rs564398 PTPLAD2 1,409 7,774
rs2237892 KCNQ1 CARS 1,414 7,779
rs2237892 KCNQ1 NAP1L4 1,955 7,864
rs7961581 TMEM19 2,243 7,842
rs4607103 PSMD6 2,630 7,790
rs4506565 TCF7L2 PDCD4 3,496 7,445
rs7901695
rs7903146
rs2237892 KCNQ1 MRGPRE 3,615 7,394
rs13266634 SLC30A8 THRAP6 4,001 7,211
rs7578597 THADA ZFP36L2 4,266 7,117
rs12255372 TCF7L2 RBM20 4,870 6,788
rs864745 JAZF1 HOXA13 5,330 6,535
rs10010131 WFS1 STK32B 5,457 6,470
rs12779790 SEC61A2 7,895 4,828
ΔRank, the difference between type 2 diabetes coexpression rank and
background rank; T2D coexpression rank, the rank of each gene’s type
2 diabetes coexpression score
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The genes in the 99th percentile cut-off that mapped to
WTCCC are listed in Table 3. Eight of these genes have
eSNPs with p<0.05 for type 2 diabetes. Two (HMGCS1,
IDI1) are involved in steroid synthesis and one (KHK) is
involved in monosaccharide metabolism.
Discussion
GWASs are revealing increasing numbers of loci associated
with various diseases. However, our understanding of the
biological mechanisms behind these genetic variants is, in
many cases, incomplete. eQTLs have the potential to aid in
deciphering these variants by associating them with gene
expression.
Although a recent study discovered no significant eQTL
relationships for well-known type 2 diabetes SNPs in colon,
pancreas or liver tissue [23], our initial analysis of type 2
diabetes expression traits revealed several such examples.
This most likely reflects the large number of individuals
from whom we could collect samples, as well as our inclu-
sion of adipose tissue in this study. For instance, the expres-
sion of TCF7L2 is not associated with any of the SNPs
studied, but there are several genes, including VTI1A,
PDCD4 and CASP7, whose expression is associated with
SNPs in TCF7L2. VTI1A, which we observed as an expres-
sion trait of the TCF7L2 SNP in omental adipose tissue, is a
vesicle-soluble NSF attachment protein receptor (v-SNARE)
that is a component of insulin-sensitive GLUT4-containing
vesicles and affects insulin-dependent glucose transport in
adipocytes [24]; PDCD4, another expression trait of the same
SNP, plays a crucial role in pancreatic beta cell death in type 1
diabetes [25]; CASP7 has also been identified as a positional
candidate gene for type 1 diabetes [26]. All of these expres-
sion traits could serve as causal explanations of how the
TCF7L2 SNP leads to type 2 diabetes.
As another example, rs1111875 and rs5015480, variants
located close to the HHEX gene, are actually associated with
the expression of IDE (encoding insulin-degrading enzyme)
in subcutaneous fat. This association suggests that the func-
tional significance of these SNPs in type 2 diabetes is
relayed through the expression of IDE, which plays a central
Fig. 2 (a) Enrichment of pT2D<0.05 at increasing type 2 diabetes
coexpression score quantiles. The genes in each quantile were ordered
by decreasing Δrank, then split at the median Δrank. The genes in
each half quantile were connected to eSNPs using eQTL datasets
mapped in liver, omental and subcutaneous adipose tissue. The blue
and red points represent, respectively, the pT2D<0.05 for the top and
bottom halves. To estimate the null distribution, we randomly selected
half of the genes in each group 10,000 times and observed the pT2D<0.05
for each sample. The violin plots represent the distribution of the
permutations for each set of genes. The separation between the top
and bottom halves as the threshold is increased suggests that the
coexpression rank, coupled with the Δrank, is a useful metric for
selecting genes relevant to the disease process. p00.12 for 97.5
percentile; p00.007 for 99 percentile. (b) Estimation of the null distribu-
tion by permuting the initial expression traits. As another estimate of the
null distribution, we randomly selected 33 genes as the initial expression
traits. As in (a), we then observed the pT2D<0.05 in WTCCC data for the
top half of genes at each cut-off for each sample. The violin plots
represent the distribution of this value at each cut-off for each sample.
We repeated this permutation analysis 1,000 times. p00.066 for 97.5
percentile; p00.026 for 99 percentile. (c) Validation of results using an
independent dataset. To validate our findings shown in (b), we repeated
the permutation analysis using data obtained from the GENEVA diabetes
study. p00.13 for 99.5 percentile; p00.042 for 99.75 percentile. Blue
diamond, pT2D<0.05 for genes with change in rank greater than quantile
median; red diamond, pT2D<0.05 for genes with change in rank less than
quantile median. T2D, type 2 diabetes

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role in insulin metabolism [27]. In other words, explaining
GWAS findings using eSNPs, as demonstrated here, might
help to distinguish between two nearby genes with radically
different potential mechanisms for disease.
Finally, rs564398, a variant in CDKN2B antisense RNA 1
(CDKN2B-AS1), is associated with the expression ofCDKN2A
in omental adipose tissue and PTPLAD2 in liver. A recent
study reported that this SNP was associated with the expres-
sion of CDKN2B-AS1 but not CDKN2A/B in peripheral
blood [28]; our result may be specific to the tissue types
that we investigated. Here, our analysis using eSNPs sug-
gests several different candidate mechanisms across separate
tissues; it could be that higher-significance variants for type
2 diabetes play their role through distinct mechanisms in
multiple relevant tissues.
In this study, we devised a ranking system that uses these
type 2 diabetes expression traits in combination with coex-
pression networks in metabolically important tissues to dis-
cover novel genes associated with type 2 diabetes. By
combining eQTL datasets from two different studies, we
discovered that eSNPs regulating highly ranked genes in
these tissues had a significant rising trend for association
with type 2 diabetes in two well-known GWASs, specifically
those performed by the WTCCC and GENEVA initiative.
While the trend observed in the GENEVA study reached
significance at a higher quantile cut-off, we think this is still
sufficient to confirm our findings.
Having thus confirmed our hypothesis, we reasoned that
the highly ranked genes that were not even marginally
associated with type 2 diabetes in a GWAS might also be
relevant to the pathogenesis of type 2 diabetes. We therefore
investigated the other novel genes highlighted by our algo-
rithm. Many of these novel genes that we identified are
primarily expressed in skeletal or cardiac muscle. Several
of these are involved in insulin signalling or glucose metab-
olism. For example, Ca2+ influx through L-type Ca2+ chan-
nels (CACNA1S) is essential for glucose-stimulated insulin
secretion [29], while sarcosin (KBTBD10) is a cytoskeletal
protein that, like VTI1A, is associated with the insulin-
stimulated glucose transporter GLUT4; interestingly, this
association is suppressed in the presence of insulin [30].
PYGM (phosphorylase, glycogen, muscle) and PFKM
(phosphofructokinase, muscle) are key enzymes in glyco-
genolysis and glycolysis.
We also discovered several genes involved in cholesterol
(INSIG1, insulin induced gene 1; HMGCS1, HMG-CoA
synthase 1; IDI1, isopentenyl diphosphate isomerase 1)
and fatty acid (FADS2, fatty acid desaturase 2; ECHDC1,
enoyl CoA hydratase domain containing 1) metabolism. In
particular, FADS2 activity has been linked to the risk of
developing type 2 diabetes [31].
Fructokinase (KHK) is another interesting candidate gene
revealed by our analysis. The endproduct of KHK is fructose-
1-phosphate, which accelerates release of glucokinase (GK)
from its regulatory protein (GKRP) [32]. Glucokinase serves
as an insulin sensor in the pancreatic beta cells and is being
evaluated as a potential drug target for type 2 diabetes [33].
The method presented here represents a paradigm for
using eQTLs and prior knowledge of SNPs associated with
a disease to discover additional candidate genes and variants
for that disease. The strength of this approach lies in the fact
that it incorporates the functional significance of the SNPs
Table 3 Top 30 candidate type 2 diabetes genes, out of 6,005, with the
selected type 2 diabetes expression traits with which they are
coexpressed
Gene containing
T2D SNP
Expression
trait
Coexpressed
candidate gene
Coexpression
rank
ΔRank
TCF7L2 VTI1A TNNC1 14 1,492
TCF7L2 CASP7 KBTBD10 19 1,886
TCF7L2 DCLRE1A PGAM2 21 1,960
KCNQ1 TNNT3 CKMT2 32 2,020
WFS1 MRFAP1 HRC 37 1,457
KCNQ1 NAP1L4 TXLNB 38 1,230
SLC30A8 THRAP6 TCAPa 54 2,668
WFS1 CPZ RYR1 55 1,241
THADA ZFP36L2 FRYa 60 2,624
KCNQ1 KCNQ1 LMOD2 63 1,465
KCNQ1 CARS CACNA1S 64 3,171
JAZF1 TAX1BP1 ECHDC1 65 3,189
TCF7L2 PDCD4 NAV2 66 2,535
WFS1 STK32B TMPRSS4 67 1,798
KCNQ1 TH MLF1 72 1,628
Intergenic CDKN2A KIAA0323b 78 1,850
KCNQ1 SLC22A18 ANKRD33 87 3,086
Intergenic TSPAN8 PYGM 88 2,481
KCNQ1 MRGPRE IDI1a 89 1,220
Intergenic TMEM20 MTHFD1L 97 2,701
Intergenic SEC61A2 HMGCS1a 98 1,927
Intergenic PSMD6 CD44a 106 1,321
TCF7L2 GPAM LMCD1 107 2,950
WFS1 JAKMIP1 PTGDRa 109 4,974
JAZF1 HOXA13 FADS2 114 1,529
Intergenic ADAMTS9 MYOM1a 117 1,754
Intergenic IDE PDLIM3 119 2,177
TCF7L2 CASP7 INSIG1 120 1,529
KCNQ1 KCNQ1 PFKM 121 2,902
Intergenic PTPLAD2 KHKa 124 2,722
Coexpression rank, the rank of the type 2 diabetes coexpression score
for each gene ΔRank, the difference between type 2 diabetes coex-
pression rank and background rank
a Any linked eSNP with p<0.05 in WTCCC
bAlso known as KHNYN
T2D, type 2 diabetes
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encapsulated in the association of eQTLs and expression
traits. In addition, using coexpression networks constructed
in various tissues enables the discovery of candidate genes
not expressed in the tissues used for mapping eQTLs. As the
number and quality of tissue-specific eQTL studies increase
and improve, we anticipate that the power of this type of
analysis to detect novel associations will also be enhanced
dramatically. This highlights once again the importance of
making this type of data available, so that the greater com-
munity of scientists may benefit.
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